Latest News


Filter by tags: Neoplasm Clear all tag filters

11 news articles found

October's harvest of cobalt-60, used worldwide to sterilise medical equipment, was the largest since the company began producing the isotope in the 1980s and included two shipments of medical-grade material for therapeutic use.

Date: Saturday, 25 November 2023
Original article:

Germany-based radiopharmaceutical biotech company ITM Isotope Technologies Munich SE and Canadian Nuclear Laboratories (CNL) have launched Actineer, a joint venture for the industrial-scale production of actinium-225 (Ac-225).

Date: Friday, 20 October 2023
Original article:,-ITM-join-up-to-produce-rare-medical-radioisot

TerraPower Isotopes and Belgian joint venture PanTera have announced a collaboration to increase the global availability of actinium-225 (Ac-225), while Arizona-based Serva Energy has developed a new research reactor-based production method to ramp up the supply of the rare radioisotope.

Date: Wednesday, 28 June 2023
Original article:

Advances in emerging field of ‘theranostics’ are a game-changer Millions of patients around the globe rely on the regular and timely production of diagnostic and therapeutic isotopes produced in research reactors and accelerator facilities. Image courtesy IAEA. Advances in medical isotope diagnostics and therapy are holding promise for cancer patients, despite challenges facing the nuclear medical field in recent years related to radionuclide production and supply, rising costs, and stricter regulation.

Medical isotopes are radioactive substances used in various diagnostic and therapeutic procedures to treat various types of cancers and other conditions. They are essential for modern medicine, allowing physicians to visualise and target specific organs, tissues and cells in a patient’s body.

Over more than a decade, personalised medicine using nuclear techniques has been gaining pace, allowing doctors to tailor therapies and treatments to the specific needs and physiology of a patient, and to avoid harm to healthy organs or tissues.

According to Sven Van den Berghe, chief executive of Belgium-based isotope producer PanTera, one technique that has seen significant advances is known as theranostics – the term used to describe the combination of using one radioactive drug to diagnose and a second to deliver therapy to treat the main tumour and any metastatic tumours.

Date: Friday, 14 April 2023
Original article:

The production of cobalt-60 is critical to healthcare and, with demand soaring, the challenge is to expand supply, writes Martin Comben from the International Irradiation Association.

Date: Wednesday, 29 March 2023
Original article:

The commercial production of lutetium-177 (Lu-177) has begun using a new isotope production system (IPS) that was installed in unit 7 of the Bruce plant in Ontario, Canada, during a planned maintenance outage earlier this year.

Date: Thursday, 27 October 2022
Original article:

Lutetium-177 (Lu-177) has been produced using a new isotope production system (IPS) that was installed in unit 7 of the Bruce plant in Ontario, Canada, during a recent planned maintenance outage. It marks the first time the short-lived medical isotope has been produced in a commercial nuclear power reactor.

Date: Thursday, 23 June 2022
Original article:

The nuclear medicine sector is a small part of the wider nuclear industry, but it provides some of the most pioneering technologies in healthcare - and is close to making personalised medicine a reality. Antonis Kalemis, president of Nuclear Medicine Europe and business manager for molecular imaging at Siemens Healthineers, describes how nuclear medicine also tackles the most trenchant condition in modern healthcare: cancer.

Date: Thursday, 29 July 2021
Original article:

The Dutch medical device company Quirem Medical recently started using the BR2 research reactor at the SCK CEN nuclear research centre for the production of QuiremSpheres, SCK CEN said on 15 June. QuiremSpheres are used for treating liver cancer and consist of small radioactive spheres loaded with holmium-166. In 2020, more than 905,000 people across the world were diagnosed with primary liver cancer, and 830,180 liver cancer patients died. A promising treatment is the use of a therapeutic radioisotope: holmium-166. This radioisotope is injected into the hepatic artery in the form of millions of tiny spheres - each one smaller than a human hair. The holmium spheres, called holmium microspheres, accumulate in the tiniest capillaries of the liver tumours and locally emit their radiation there. The tumours shrink or disappear, while the surrounding healthy liver tissue is spared. Patients with liver cancer for whom surgery is not an option are eligible for this treatment, also known as selective internal radiotherapy (SIRT).

Date: Friday, 18 June 2021
Original article:

TRIUMF, Canada’s particle accelerator centre, and Canadian Nuclear Laboratories (CNL) announced on 27 September that they have agreed to pursue a strategic partnership around the commercial production of the medical isotope, Actinium-225, as the basis of new cancer treatments. Actinium-225 is an alpha-emitting isotope with a short half-life that can be combined with a protein or antibody that specifically targets cancer cells.

Date: Tuesday, 02 October 2018
Original article: